Table 1.
Telomere length and its association with critically ill COVID‐19 in the MR analyses
| Exposure | Outcome | No. of SNPs | Methods | OR (95% CI) | β (SE) | p |
|---|---|---|---|---|---|---|
| The forward MR analyses | ||||||
| Critically ill COVID‐19 | LTL | 6 | IVW | 0.0075 (0.0220) | 0.734 | |
| MR‐Egger | −0.0006 (0.0571) | 0.992 | ||||
| Weighted median | −0.0095 (0.0141) | 0.497 | ||||
| Weighted mode | −0.0199 (0.0142) | 0.220 | ||||
| The reverse MR analyses | ||||||
| LTL | Critically ill COVID‐19 | 97 | IVW | 1.00 (0.79–1.28) | 0.004 (0.125) | 0.973 |
| MR‐Egger | 1.19 (0.78–1.81) | 0.174 (0.213) | 0.415 | |||
| Weighted median | 1.28 (0.86–1.90) | 0.249 (0.202) | 0.217 | |||
| Weighted mode | 1.29 (0.87–1.94) | 0.258 (0.205) | 0.211 | |||
Abbreviations: CI, confidence interval; IVW, inverse variance weighted; LTL, leukocyte telomere length; MR, Mendelian randomization; OR, odds ratio; SNPs, single‐nucleotide polymorphisms.